BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Boehringer Ingelheim International GmbH submitted on 4 June 1997 an application for 
the marketing authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for  Viramune  (nevirapine)  200  mg  tablet  through  the  centralised  procedure.  After  agreement  by  the 
CPMP on 16 October 1996, this medicinal product is referred to Part B of the Annex of the Council 
Regulation (EEC) 2309/93, of the 22 July 1993.  
The Rapporteur and the Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Prof. M. Forte 
Co-Rapporteur: 
Pharm. G. De Greef 
Licensing status:  
Viramune is licensed in several non-EU countries including USA in 21 June 1996. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product  
The procedure started on 20 June 1997. 
The Rapporteur’s assessment report was circulated to all CPMP members on 
4 September 1997. The Co-Rapporteur’s assessment report was circulated to all CPMP members 
on 5 September 1997. 
The  preliminary  Rapporteur’s  and  Co-Rapporteur’s  overall  recommendation  on  the  medicinal 
product was circulated to all CPMP members on 14 October 1997. 
The  applicant  provided  on  16  October  1997  to  all  CPMP  members,  responses  on  outstanding 
pharmaceutical and clinical issues. 
On the basis of the responses provided by the company, the final Rapporteur and 
Co-Rapporteur recommendation was circulated on 20 October 1997. 
A hearing was held on 21 October 1997, during the plenary CPMP meeting, where the company 
addressed in particularly the therapeutic role of Viramune and the strategy for the inclusion of 
nevirapine in combination regimens.  
The  applicant,  as  requested  by  the  CPMP,  signed  a  letter  of  undertaking  on  the  specific 
obligations and follow-up measures, on 22 October 1997. 
The CPMP, in the light of the overall data submitted and the scientific discussion considered the 
provisional risk/benefit to be favourable and issued on 22 October 1997 a positive opinion for 
granting the Marketing Authorisation under exceptional circumstances. 
The  CPMP  opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding decision on 5 February 1998. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
